1, the estimated market value is not less than RMB 1 billion, the net profit in the last two years is positive and the accumulated net profit is not less than RMB 50 million, or the estimated market value is not less than RMB 65,438 billion, and the net profit in the last year is positive and the operating income is not less than RMB 1 billion;
2. The estimated market value is not less than RMB 654.38+05 billion, the operating income in the latest year is not less than RMB 200 million, and the accumulated R&D investment in the last three years accounts for not less than 654.38+05% of the accumulated operating income in the last three years;
3. The estimated market value is not less than RMB 2 billion, the operating income in the latest year is not less than RMB 300 million, and the accumulated net cash flow generated by operating activities in the last three years is not less than RMB 654.38+0 billion;
4. The estimated market value is not less than 3 billion yuan, and the operating income in the latest year is not less than 300 million yuan;
5. The estimated market value is not less than 4 billion yuan, and the main business or products need to be approved by the relevant state departments, so the market space is large. Enterprises in the pharmaceutical industry need to have at least one core product approved for Phase II clinical trials, and other enterprises that meet the positioning of the science and technology innovation board need to have obvious technological advantages and meet the corresponding conditions.